Supplementary file 1_Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.docx
Background<p>Cabozantinib combined with atezolizumab has been shown to prolong progression-free survival in first-line treatment of advanced hepatocellular carcinoma (HCC). However, the cost-effectiveness of this regimen remains unknown. This study aimed to evaluate the cost-effectiveness of c...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|